PeerView Oncology & Hematology CME/CNE/CPE Video Podcast
611 episodes - English - Latest episode: 11 days ago - ★★★★★ - 7 ratingsPeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.
Homepage Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed
Episodes
Matthew T. Ballo, MD, FACR - Modernizing Your Radiation Oncology Practice With Tumor Treating Fields and Other Novel Multimodal Strategies: Understanding the Science, Evidence, and Practical Aspects Across a Range of Solid Tumors
December 16, 2021 23:00 - 1 hour VideoGo online to PeerView.com/KGF860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. New treatment modalities such as tumor treating fields (TTFields) and innovative combination strategies are revolutionizing the therapeutic management of solid tumors. This new modality of alternating electric fields therapy is FDA approved in GBM and MPM and is paving the way for improved outcomes in other solid tumors. As this previously unrecognized antimito...
Joyce O’Shaughnessy, MD - Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors
December 16, 2021 23:00 - 1 hour VideoGo online to PeerView.com/HYM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Orally bioavailable CDK4 and 6 inhibitors have become established standard-of-care options in HR+/HER2- metastatic breast cancer, and these agents are now expected to have a major impact in early breast cancer (EBC). CDK4 and 6 inhibition has recently shown significant benefit as adjuvant therapy in patients at high risk of early recurrence, but other studies i...
Javid Moslehi, MD - Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared?
December 16, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/AZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView Clinical Consults activity features cardio-oncologist Javid Moslehi, MD, and medical oncologist Douglas B. Johnson, MD, MSCI, who explain why greater awareness is needed among cardiology professionals about the cardiac toxicities associated with cancer immunotherapies, known as immune-related adverse events (irAEs), and their clinical manifestatio...
David R. Jones, MD - Turning Tides in Targeted Therapy for Early-Stage EGFR-Mutated NSCLC: Latest Data and Practical Guidance for Thoracic Surgeons and the Multidisciplinary Team on the Emerging Role of EGFR-Targeted Therapy in Resectable Lung Cancer
December 14, 2021 23:00 - 57 minutes VideoGo online to PeerView.com/ZUJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In the era of precision medicine, genomic profiling to individualize management of patients with advanced non–small cell lung cancer (NSCLC) is paramount. Advances in targeted therapy in advanced/metastatic NSCLC have heightened interest in expanding its use into earlier stages of the disease to improve outcomes in curative intent settings. Subsequently, a grow...
Ronan J. Kelly, MD, MBA - Preparing for the Next Leap Forward in Multimodal Management of Esophageal/GEJ Cancer: An Interdisciplinary Tumor Board on Adjuvant Immunotherapy
December 11, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/DCQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Esophageal cancer has a poor prognosis with 5-year survival rates below 35% in the non-metastatic setting. Despite the use of trimodality approaches with chemotherapy, radiation, and surgery, survival benefits remain suboptimal. Promisingly, recent phase 3 evidence suggests that adjuvant immunotherapy can significantly improve disease-free survival in patients ...
Jubilee Brown, MD - Changing Tides in Advanced Endometrial Cancer: A Visual Exploration of Current and Emerging Strategies to Maximize the Potential of Cancer Immunotherapies
December 09, 2021 23:00 - 33 minutes VideoGo online to PeerView.com/YBS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in endometrial cancer examines the evidence for current and emerging treatment strategies and shares evidence-based recommendations for maximizing the potential of immunotherapies to improve outcomes for patients with advanced endometrial cancer. Upon completion of this activity, participants should be better able to: Descr...
Nirav Shah, MD, MS - Visualizing Progress With BTK Inhibitors: An Animated Journey Through the Mechanisms of Covalent and Noncovalent Options
December 09, 2021 23:00 - 22 minutes VideoGo online to PeerView.com/AMC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. It’s well known that the BTK inhibitor agent class is highly effective across several B-cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma. Less well understood are the factors that can limit the effectiveness of covalent BTK inhibitors and the emerging strategies that can overcome therapeutic resistance and intolerance, which pr...
Lynette M. Sholl, MD - Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings
December 08, 2021 23:00 - 58 minutes VideoGo online to PeerView.com/KPW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Rapid progress in the treatment of EGFR-mutated non–small cell lung cancer (NSCLC) has practice-changing implications for pathologists, oncologists, and the broader multidisciplinary lung cancer care team. In addition to multiple targeted therapy options available for patients with metastatic NSCLC with more commonly occurring EGFR mutations, new agents have re...
Erik P. Sulman, MD, PhD - Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers
December 08, 2021 23:00 - 1 hour VideoGo online to PeerView.com/QNS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Novel medical technologies have revolutionized the therapeutic management of difficult-to-treat cancers. In particular, tumor treating fields (TTFields) therapy, which is a state-of-the-art, noninvasive modality that harnesses low intensity alternating electric fields to selectively disrupt tumor cell division and migration, has demonstrated clear benefits in t...
Roger J. Packer, MD - Progressive Pathways: Recent Recommendations and Emerging Therapies for Treating NF1-Associated Tumors
December 07, 2021 23:00 - 1 hour VideoGo online to PeerView.com/AGQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Neurofibromatosis type 1 (NF1) is an incurable genetic disorder that primarily gives rise to nervous system tumors but can also lead to multisystem involvement. Neurofibromas are a key feature of NF1, and approximately 50% of patients will develop plexiform neurofibromas (PNs), which are associated with substantial morbidity and carry the potential to transform...
Ronan J. Kelly, MD, MBA & Daniela Molena, MD - Immunotherapy at the Cutting Edge in Resectable Esophageal/GEJ Cancer: Preparing Thoracic Surgeons and the Broader Multidisciplinary Team to Navigate Changing Standards of Care
December 06, 2021 23:00 - 1 hour VideoGo online to PeerView.com/KZR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you integrating the latest optimal treatments into the management plans for your patients with esophageal/gastroesophageal junction (GEJ) cancer? The approval of the PD-1 inhibitor nivolumab in the adjuvant setting has provided a new opportunity for patients to achieve longer disease-free survival, a goal that had not been attainable with conventional modal...
Jonathan W. Goldman, MD - Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?
November 29, 2021 23:00 - 1 hour VideoGo online to PeerView.com/KBM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, three experts provide useful updates and practical guidance to maximize the potential of the therapeutic progress achieved with immune checkpoint inhibitors in small cell lung cancer to date, as well as insightful expert analysis of what’s showing the most promise next. Clinical and research updates are combined with case-based demonstrations ...
Prof Eric Van Cutsem, MD, PhD - Putting a Personalized Colorectal Cancer Treatment Algorithm Into Practice: Navigating Practicalities in the Era of Molecularly Defined Care
November 16, 2021 23:00 - 1 hour VideoGo online to PeerView.com/JEN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discuss clinical decision-making, current guideline recommendations for biomarker testing, and the potential utility of such testing in improving disease management and clinical outcomes in patients with colorectal cancer. Upon completion of this activity, participants should be better able to: Evaluate the latest clinical d...
Andrew J. Wagner, MD, PhD - Overcoming the Challenges of Diverse TGCT Presentations: Diagnostic and Treatment Principles for the Multidisciplinary Team
November 09, 2021 23:00 - 35 minutes VideoGo online to PeerView.com/AEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the widespread use of surgery as a standard of care for tenosynovial giant cell tumor (TGCT), several therapeutic challenges remain, particularly in the setting of diffuse TGCT, where recurrent and difficult-to-treat disease can be present. In this activity, an orthopedic surgeon and medical oncologist debate the case-based management of challenging TGC...
Kurt A. Schalper, MD, PhD - Evolving Standards in Biomarker Testing, Scoring, and Results Interpretation Driven by the Broadening Role of Cancer Immunotherapy
November 05, 2021 23:00 - 1 hour VideoGo online to PeerView.com/QRC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss IO biomarkers. Upon completion of this accredited CE activity, participants should be better able to: Discuss the rationale for and practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays, cut-points, and other nuance...
Peter A. Kouides, MD - Advancing Treatment of von Willebrand Disease: A Visual Exploration on Personalizing Care With Current and Emerging Management Strategies
October 25, 2021 23:00 - 27 minutes VideoGo online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic wo...
Melissa L. Johnson, MD - Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC
October 19, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/ANP860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The treatment arsenal for NSCLC with and without genomic alterations is continuously growing, and novel HER2-, HER3-, and TROP2-targeting antibody–drug conjugates, among other agents, are showing great promise for improving outcomes in challenging subgroups of patients with lung cancer. Extensive and nuanced biomarker testing has never been more important in gu...
Srdan Verstovsek, MD, PhD / Ruben A. Mesa, MD, FACP - Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics
October 19, 2021 23:00 - 1 hour VideoGo online to PeerView.com/ZZW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in myelofibrosis discuss risk stratification, individualized care, and treatment strategies, including the use of JAK inhibitors and JAK inhibitor–based combinations. Upon completion of this accredited CE activity, participants should be better able to: Review modern risk stratification models, molecular features, cytogenetics, and cli...
Nicole Lamanna, MD / Jennifer Woyach, MD - Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential Care
October 19, 2021 23:00 - 1 hour VideoGo online to PeerView.com/QZB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in chronic lymphocytic leukemia (CLL) management discuss the current evidence and clinical data supporting the use of first- and second-generation BTK inhibitors in CLL. The experts use this evidence to build a series of case scenarios designed to illustrate how professionals can seize the opportunity to personalize BTK inhibitor u...
Anthony R. Mato, MD, MSCE - Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies
October 14, 2021 23:00 - 1 hour VideoGo online to PeerView.com/ECV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematologist-oncologist, cardiologist, oncology nurse, and pharmacist team up to discuss targeted agents (including BTK and BCL-2 inhibitors) in B-cell malignancies and how the team works closely together to manage toxicity and safety concerns associated with targeted therapies. Case scenarios are presented to illustrate how a collaborative ...
Sagar Lonial, MD, FACP - Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care
October 13, 2021 23:00 - 1 hour VideoGo online to PeerView.com/JBG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView webcast, an expert panel consisting of a hematologist-oncologist, pharmacist, oncology nurse, and ophthalmologist use a “center of excellence” model to illustrate how the real-world, intra-institutional management of challenging multiple myeloma (MM) cases has changed in the wake of advances based on CD38 and BCMA-targeting antibody options. Th...
Jared Weiss, MD - Raising the Bar for Patient Outcomes With Transcription Inhibition and Other New Options in the Treatment Arsenal for SCLC: Rationale, Mechanisms of Action, Latest Data, and Practicalities of Clinical Use in Oncology Practice
October 12, 2021 23:00 - 54 minutes VideoGo online to PeerView.com/DJB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. What’s new in the treatment of small cell lung cancer (SCLC), and how can healthcare professionals make the most of the accelerating therapeutic progress to maximize benefits for patients? For many years, SCLC was viewed as a challenging subtype of lung cancer, with limited treatment advances and poor outcomes, but recent developments have brought new options a...
Milind Javle, MD - Taking Action in Advanced Biliary Cancers: Expert Insights on Integrating Newly Available and Innovative Therapeutics to Deliver Precision-Based Care
October 12, 2021 23:00 - 27 minutes VideoGo online to PeerView.com/GEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert discusses the latest data on targeted treatments for biliary cancers and integrating precision medicine with new and emerging strategies. Upon completion of this accredited CE activity, participants should be better able to: Describe the biologic rationale for the use of targeted options in the management of advanced biliary cancers, such as those tar...
Anthony R. Mato, MD, MSCE - The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL
October 11, 2021 23:00 - 1 hour VideoGo online to PeerView.com/QXD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the success of BTK inhibitor therapy in B-cell malignancies, therapeutic resistance and intolerance represent barriers to effective, sustained anticancer therapy. What can clinicians do in the face of this challenge? In this case-based “Clinical Consults” discussion, a panel of leading experts meet this challenge head on and provide guidance on how to p...
Kenneth R. Cooke, MD - Collaborative Strategies for Managing VOD/SOS: Interprofessional Insights on Advances in Diagnosis, Severity Grading, and Treatment
October 11, 2021 23:00 - 51 minutes VideoGo online to PeerView.com/PGX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in blood and marrow transplantation illuminate the roles of various members of the transplant team in the overall approach to diagnosing and treating VOD/SOS, while also offering learners a window into how hematologist-oncologists, transplant specialists, advanced practice clinicians, radiologists, pathologists, nurses, pharmacists, an...
R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA/ Kathryn Maples, PharmD, BCOP / Tim J. Peterson, PharmD, BCOP -Making Sense of the New World of Myeloma Care: Pharmacy Perspectives on Novel Antibodies and BCMA CAR-T Therapy
October 08, 2021 23:00 - 1 hour VideoGo online to PeerView.com/WST860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of pharmacy experts in multiple myeloma management discusses the latest evidence on novel antibody and CAR-T options and link key take-homes from the data to core aspects of pharmacy practice, from minimizing adverse events/drug interactions to educating patients and staff while addressing other pharmacy considerations. Upon completion...
Stephen V. Liu, MD - Maximizing the Potential of Immunotherapy in Multimodal Management of Unresectable Stage III NSCLC: Collaboration Is Crucial, Patient Selection Is Paramount, Close Monitoring Is Critical
October 06, 2021 23:00 - 1 hour VideoGo online to PeerView.com/DDV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The broad implications of the expanding role of cancer immunotherapies in lung cancer necessitate multidisciplinary collaboration, especially in the locally advanced setting where appropriate patient evaluation and selection for immune checkpoint inhibitors (ICIs) along with other multimodal therapies requires input from a medical oncologist, a radiation oncolo...
Sanam Loghavi, MD - Secondary AML Through the Microscope: A Pathology-Informed Guide to Modern Diagnostic and Treatment Principles
October 06, 2021 23:00 - 28 minutes VideoGo online to PeerView.com/SFE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert pathologist discusses secondary acute myeloid leukemia (AML) as well as the modern tools used in diagnostic assessment that can help facilitate appropriate risk stratification and collaborative treatment decisions so therapies beyond conventional chemotherapy options can be considered. Upon completion of this accredited CE activity, ...
Stephen V. Liu, MD - Tracking All the Targets in Genomically Altered NSCLC: Everything You Need to Know About Biomarker Testing and Treatment
September 29, 2021 23:00 - 1 hour VideoGo online to PeerView.com/EYW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Comprehensive biomarker profiling of complex and heterogeneous tumors such as non–small cell lung cancer (NSCLC) is crucial for determining the best therapeutic approach for each patient. In metastatic NSCLC, the number of molecular alterations that have FDA-approved matched therapies has been rapidly growing. The first targeted therapy has received regulatory ...
Jamie E. Chaft, MD - Marking New Milestones With Immunotherapy in Locally Advanced and Early Lung Cancer: Latest Data Informing Best Practices for Multimodal Management of Stage I-III NSCLC
September 29, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/CBB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The immunotherapy revolution in lung cancer continues, as clinical practice and research build on achievements made in advanced NSCLC and aim to extend the benefits of immunotherapies to earlier stages. Immune checkpoint inhibitor (ICI) therapy is routinely used as consolidation following chemoradiation for patients with stage III unresectable NSCLC. Now, ICIs ...
Gail J. Roboz, MD - Clinical Consults on Modern AML Therapy: Where Precision Care Meets Potent Therapeutics
September 28, 2021 23:00 - 1 hour VideoGo online to PeerView.com/GXY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this Clinical Consults webcast, a panel of experts looks at modern AML therapeutics that have transformed practice in high-risk, good-prognosis, mutation-defined, and post-remission settings (such as TP53-mutant AML, IDH and FLT3 mutation-positive disease, among others). Our experts offer guidance on how disease biology drives treatment decisions and on the ...
Nina Shah, MD - Innovation at Warp Speed for Multiple Myeloma: Tumor Board Insights on State-of-the-Art Care
September 28, 2021 23:00 - 1 hour VideoGo online to PeerView.com/XTT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of multiple myeloma experts discuss the recent changes in the multiple myeloma (MM) treatment landscape that have occurred at “warp speed” by focusing on the emergence of novel antibodies, cellular therapy, and targeted strategies across the MM treatment continuum. Throughout, the panelists engage in dedicated Tumor Board sessions desi...
Manish A. Shah, MD, FASCO - Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy
September 15, 2021 23:00 - 59 minutes VideoGo online to PeerView.com/WNZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. As the treatment landscape for gastric and gastroesophageal junction (GEJ) cancers continues to evolve, patients with these heterogenous and aggressive malignancies are benefiting from improved outcomes. Targeted therapies, such as anti-angiogenic agents, have had a beneficial role in the second-line gastric and GEJ cancer settings after prior fluoropyrimidine-...
Ian W. Flinn, MD, PhD - Visualizing the Present and Future of CLL: How Innovative Therapies and State-of-the-Art Combinations Are Transforming Patient Care
September 13, 2021 23:00 - 25 minutes VideoGo online to PeerView.com/NZY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Modern management of chronic lymphocytic leukemia (CLL) has been transformed by innovative therapeutics, including BTK and BCL-2 inhibitors, in a range of patient populations and treatment settings—but what is the next step? In this activity, an expert clinician addresses that question and reviews evidence on emerging targeted options and novel combination stra...
Ruben A. Mesa, MD, FACP - A Personalized Approach to Guide Risk-Adapted Treatment Decisions in Myelofibrosis: Applying the Latest Clinical Evidence on JAK Inhibitors and Novel Combination Therapies to Improve Patient Outcomes
September 10, 2021 23:00 - 37 minutes VideoGo online to PeerView.com/CCY860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, hematology-oncology experts discuss the current and emerging therapeutic options for the management of patients with myelofibrosis. Upon completion of this accredited CE activity, participants should be better able to: Describe the molecular genetics, cytogenetics, and clinical features of myelofibrosis as well as modern prognostic scoring sys...
Laura J. Zitella, MS, RN, ACNP-BC, AOCN - Taking the Fight to AML: Oncology Nurse Perspectives, Principles, and Practice in an Era of Innovative Therapies
August 31, 2021 23:00 - 55 minutes VideoGo online to PeerView.com/ESW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two expert nurse panelists use case-based teaching to illustrate solutions to clinical challenges associated with nursing care in the modern acute myeloid leukemia (AML) treatment landscape in which innovative therapies (including targeted agents, newer cytotoxics, and epigenetic approaches) are now core patient treatment strategies. Upon comp...
Alok A. Khorana, MD, FACP, FASCO / Robert D. McBane, II, MD - Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care and Shared Decision-Making Strategies to Improve Patient Outcomes
August 17, 2021 23:00 - 46 minutes VideoGo online to PeerView.com/NWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss the diagnosis of cancer-associated VTE, review the latest data and guidelines on currently available treatment options, and suggest strategies for including interprofessional collaboration in routine clinical practice. Upon completion of this accredited CE activity, participants should be better able to: Assess the ...
Nicola Gökbuget, MD - Achieving Therapeutic Innovation in ALL: Insights on Modern Asparaginase Compounds in Pediatric, AYA, and Adult Patients
August 06, 2021 23:00 - 1 hour VideoGo online to PeerView.com/JPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity features case-based expert discussions on the use of asparaginase in the context of broader innovations in ALL care across pediatric, AYA, and adult patients. Our experts give insights on standard asparaginase compounds, monitoring and management of toxicities, hypersensitivity/silent inactivation, and sequential use of alternati...
Jason J. Luke, MD, FACP / Geoffrey T. Gibney, MD - Building Better Models for Melanoma Care: Continued Progress With Immunotherapy in Resectable and Unresectable Disease
August 05, 2021 23:00 - 1 hour VideoGo online to PeerView.com/GZJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two melanoma experts engage in case-based discussions and scientific lecture segments on topics such as the selection of immunotherapy in metastatic disease, best practices for the use of adjuvant or neoadjuvant checkpoint blockade, and how future care will be defined by emerging science on novel immunotherapy combination approaches. Upon comp...
Suzanne Lentzsch, MD, PhD - A New Treatment Era for Light Chain Amyloidosis: Interprofessional Lessons From a Center of Excellence
July 30, 2021 23:00 - 57 minutes VideoGo online to PeerView.com/KKH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a panel of experts discusses a team-based approach to the management of light chain (AL) amyloidosis. Hear from Suzanne Lentzsch, MD, PhD, Mathew S. Maurer, MD, and Margaret Cuomo, MSN, FNP-C, from the Columbia University Medical Center, as they give insights on diagnostic strategies for AL amyloidosis and as they explore treatment guidelines,...
Sara M. Tolaney, MD, MPH - Evaluating the Evidence and Parsing the Practicalities of Therapeutic Choices in Advanced and Early HR+ Breast Cancer: Expert Perspectives on CDK4 and 6 Inhibitors and Other Novel Agents
July 30, 2021 23:00 - 1 hour VideoGo online to PeerView.com/HCT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The CDK4 and 6 inhibitors have been game-changers in the management of metastatic HR+, HER2- breast cancer, and accumulating evidence is now showing that they may also provide substantial benefits to some patients in early-stage settings, especially as adjuvant therapy for patients at high risk for disease recurrence. Various novel agents are also emerging as a...
Bruce R. Korf, MD, PhD / Nicole J. Ullrich, MD, PhD, MMSci - Translating Science to Transform Clinical Practice: How MEK Inhibitors Are Changing the Treatment Landscape of NF1 and NF1-Associated Tumors
July 26, 2021 23:00 - 1 hour VideoGo online to PeerView.com/PYS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in genomics and neuro-oncology discuss how MEK inhibitors are changing the treatment landscape of NF1 and NF1-associated tumors. Upon completion of this accredited CE activity, participants should be better able to: Review the role of the RAS/MAPK signaling pathway in the pathogenesis of NF1 and the mechanism of action of MEK inhibitor...
Deborah K. Armstrong, MD - The Expanding Advanced Ovarian Cancer Treatment Palette: Candid Conversations on Bringing PARP Inhibitors Into Clinical Practice
July 26, 2021 23:00 - 1 hour VideoGo online to PeerView.com/BDQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The availability of poly (ADP-ribose) polymerase (PARP) inhibitors has increased opportunities for healthcare professionals to improve outcomes for patients with advanced ovarian cancer through personalized medicine. With a key role in the treatment and maintenance of recurrent disease, as well as in first-line maintenance of newly diagnosed disease, PARP inhib...
Sumanta Kumar Pal, MD - New Data and Clinical Context: An Update on Renal Cell Carcinoma Care in Early Through Advanced Disease
July 22, 2021 23:00 - 30 minutes VideoGo online to PeerView.com/YFW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses new evidence from ASCO 2021 on the continuing integration of immunotherapy, targeted agents, and novel therapeutics across a wide range of renal cell carcinoma settings. Upon completion of this activity, participants should be better able to: Assess recent efficacy and safety data on new treatment approaches, including targ...
Jacob Sands, MD - Making the Most of Treatment Advances in SCLC: New Standards, Practicalities of Care, and Hope on the Horizon
July 21, 2021 23:00 - 1 hour VideoGo online to PeerView.com/FJX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is known as an aggressive, rapidly progressing, and challenging thoracic malignancy. After lacking progress for decades, recent advances have finally led to approvals of new therapies that can improve outcomes and quality of life of patients with SCLC. Chemoimmunotherapy has become the new standard of care in the first-line setting...
Joyce O’Shaughnessy, MD - Expanding the Benefits of Checkpoint Inhibitors and Targeted Agents in the Treatment Arsenal for Triple-Negative Breast Cancer
July 21, 2021 23:00 - 1 hour VideoGo online to PeerView.com/EKR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Triple-negative breast cancer (TNBC) is an aggressive cancer that has historically been associated with particularly poor patient outcomes. Fortunately, the recent validation of immunotherapies in advanced and early disease settings and the continued emergence of new targeted therapy approaches have brought hope to a patient population for whom only limited opt...
Jaffer A. Ajani, MD / Ian Chau, MD, FRCP - Gaining New Ground With Immunotherapy in the Management of Early and Advanced Gastrointestinal Cancers: Translating Progress Into Clinical Practice in Gastric, Esophageal, GEJ, and Colorectal Cancers
July 21, 2021 23:00 - 1 hour VideoGo online to PeerView.com/SXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in GI cancer discuss current and emerging roles of immune checkpoint inhibitors in GI cancers, including their biologic rationale and the latest practice-informing clinical trial evidence. Upon completion of this accredited CE activity, participants should be better able to: Explain the rationale for and current guidelines regarding th...
Sara Hurvitz, MD - Making Progress in Early and Advanced HER2-Positive Breast Cancer: Leveraging HER2-Targeted Therapies and Modern Care Principles to Improve Clinical Outcomes and Health Equity
July 16, 2021 23:00 - 1 hour VideoGo online to PeerView.com/SAA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. The number of different HER2-targeted agents and combinations in the treatment arsenal for early-stage and metastatic HER2-positive breast cancer continues to grow, offering more options for customizing the care plans for individual patients, but also making the clinical decisions about selection and sequencing of these therapies more complex. Many factors need...
Matthew S. Davids, MD, MMSc - Pushing Therapeutic Boundaries in CLL: The Convergence of Targeted Therapy, Novel Combinations, and Precision Medicine in Patient Care
July 15, 2021 23:00 - 1 hour VideoGo online to PeerView.com/JWG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This Clinical Consults activity, developed in collaboration with the CLL Society, pairs compelling, real-world case scenarios with mini lectures that focus on the meaningful science that supports the continued integration of targeted therapeutics—including BTK and BCL-2 inhibitors, as well as novel antibodies—into the management of diverse CLL patient populatio...
William G. Wierda, MD, PhD - New Standards for CLL Care With BTK Inhibitors: Using Evidence to Make Personalized Treatment Choices
July 15, 2021 23:00 - 1 hour VideoGo online to PeerView.com/SYN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this PeerView Seminar and Tumor Board activity, CLL experts discuss how BTK inhibitors are changing the treatment landscape for patients with CLL. Find out how these experts make treatment choices for upfront and relapsed disease, factoring safety into the decision to use BTK inhibitors and sequencing strategies. These clinical conversations are supported by...